Paper32034142
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.
Radhakrishnan SV and 13 others. Nat Commun, 2020. Cited by 68 papers, by iCite.
Cite this record
ConductScience Library. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Papers, record 32034142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32034142
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunotherapy, Adoptive | Major topic |
| Multiple Myeloma | Major topic |
| Receptors, Antigen, T-Cell | Major topic |
| Signaling Lymphocytic Activation Molecule Family | Major topic |
| Animals | |
| Antibodies | |
| B-Lymphocytes | |
| Humans | |
| K562 Cells | |
| Male | |
| Mice, Inbred NOD | |
| T-Lymphocytes | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K24 CA198315 | NCI NIH HHS | United States | K24CA198315 | PubMed and NIH | NIH RePORTER |
| P30 CA042014 | NCI NIH HHS | United States | P30CA042014 | PubMed and NIH | NIH RePORTER |
References2
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12374689 | Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. | Clin Cancer Res | 2002 | https://conductscience.org/library/papers/12374689 | PubMed |
| 2 | 28861320 | CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. | Am J Cancer Res | 2017 | https://conductscience.org/library/papers/28861320 | PubMed |
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 68 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42020353 | Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42020353 | PubMed |
| 41271617 | Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance. | Blood Cancer J | 2025 | https://conductscience.org/library/papers/41271617 | PubMed |
| 41052980 | Investigation of lncRNA expression in newly diagnosed multiple myeloma reveals a LINC01432-CELF2 axis as an inhibitor of apoptosis. | Oncogenesis | 2025 | https://conductscience.org/library/papers/41052980 | PubMed |
| 40597436 | Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential. | Biomark Res | 2025 | https://conductscience.org/library/papers/40597436 | PubMed |
| 40400956 | Identification of potential therapeutic drug targets for sepsis by combining the human plasma proteome and genome: a Mendelian randomization study. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/40400956 | PubMed |
| 40382610 | SLAMF receptors: key regulators of tumor progression and emerging targets for cancer immunotherapy. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40382610 | PubMed |
| 40264764 | Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias. | Front Immunol | 2025 | https://conductscience.org/library/papers/40264764 | PubMed |
| 39816951 | Development and Validation of a Diagnostic Model for Stanford Type B Aortic Dissection Based on Proteomic Profiling. | J Inflamm Res | 2025 | https://conductscience.org/library/papers/39816951 | PubMed |
| 39558776 | Are we there yet? CAR-T therapy in multiple myeloma. | Br J Haematol | 2024 | https://conductscience.org/library/papers/39558776 | PubMed |
| 39468695 | Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma. | Exp Hematol Oncol | 2024 | https://conductscience.org/library/papers/39468695 | PubMed |
| 39372412 | Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies. | Front Immunol | 2024 | https://conductscience.org/library/papers/39372412 | PubMed |
| 39095991 | T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting. | Mol Ther | 2024 | https://conductscience.org/library/papers/39095991 | PubMed |
| 38986621 | Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/38986621 | PubMed |
| 38915559 | Preventing trogocytosis by cathepsin B inhibition augments CAR T cell function. | bioRxiv | 2025 | https://conductscience.org/library/papers/38915559 | PubMed |
| 38892913 | CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects. | J Clin Med | 2024 | https://conductscience.org/library/papers/38892913 | PubMed |
| 38865708 | Beyond BCMA: newer immune targets in myeloma. | Blood Adv | 2024 | https://conductscience.org/library/papers/38865708 | PubMed |
| 38800372 | Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma. | Front Oncol | 2024 | https://conductscience.org/library/papers/38800372 | PubMed |
| 38699030 | From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma. | Heliyon | 2024 | https://conductscience.org/library/papers/38699030 | PubMed |
| 38579288 | IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. | Blood | 2024 | https://conductscience.org/library/papers/38579288 | PubMed |
| 38502423 | Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma. | Discov Oncol | 2024 | https://conductscience.org/library/papers/38502423 | PubMed |
Genes23
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32034142
GET https://conductscience.org/api/papers/v1/32034142/cited_by?page=2